Trial Profile

A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Apr 2025 According to an Anavex Life Sciences Media Release, data from this study has been featured in an oral presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East, held April 18-20, 2025 in Abu Dhabi, United Arab Emirates (UAE).
15 Jan 2025 Results presented in the Anavex Life Sciences Media Release.
15 Jan 2025 According to an Anavex Life Sciences Media Release,The Journal of Prevention of Alzheimers Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX2-73) for the treatment of early AD.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com